Updates

Fevertree

July 2017

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

The shares have soared to another high over £17 with Fevertree having triggered two broker forecast upgrades (at results in March and an AGM update in May, which noted trading was “ahead of expectations”) since our last update.No new numbers to report yet but one of the co-founders, Charles Rolls, has sold 4.5m (3.9%) shares at 1625p, raising a cool £73.1m. He retains 11.2%.While we profiled Fevertree at 714p last August, clearly with hindsight we should have buy rated the shares and previous advice to “buy the dips” has not worked out, given the near vertical rise. The current rating makes for a stratospheric PE for this year of 68.6, falling to 64.9 in FY’18 and that director sale i ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Gear4music - Results ahead of expectations

Cineworld

Fevertree - Chairman acquires 45,000 shares (March 2024)

Fevertree Drinks - Premium tonic water firm eyes $1.2bn US mixer market (March 2019)

Fevertree - Shares break to new highs (March 2017)

Fevertree Drinks - Brokers upgrade again (September 2016)

Fevertree Drinks - Purveyor of premium tonic water enjoys multiple eps upgrades (August 2016)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X